160 related articles for article (PubMed ID: 35102139)
1. Genomic characterization of functional high-risk multiple myeloma patients.
Soekojo CY; Chung TH; Furqan MS; Chng WJ
Blood Cancer J; 2022 Jan; 12(1):24. PubMed ID: 35102139
[TBL] [Abstract][Full Text] [Related]
2. Clinical and genomic characterization of Chinese patients with functional high-risk multiple myeloma: A real-world validation study.
Wang YT; Chu B; Zhou TG; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Zhao X; Wang MZ; Sun K; Bao L
Front Oncol; 2023; 13():1110693. PubMed ID: 36969050
[TBL] [Abstract][Full Text] [Related]
3. p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain).
Teoh PJ; An O; Chung TH; Vaiyapuri T; Raju A; Hoppe MM; Toh SHM; Wang W; Chan MC; Fullwood MJ; Jeyasekharan AD; Tergaonkar V; Chen L; Yang H; Chng WJ
Oncogene; 2022 Apr; 41(14):2106-2121. PubMed ID: 35190641
[TBL] [Abstract][Full Text] [Related]
4. Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.
Martello M; Poletti A; Borsi E; Solli V; Dozza L; Barbato S; Zamagni E; Tacchetti P; Pantani L; Mancuso K; Vigliotta I; Rizzello I; Rocchi S; Armuzzi S; Testoni N; Marzocchi G; Martinelli G; Cavo M; Terragna C
Blood Cancer J; 2022 Jan; 12(1):15. PubMed ID: 35082295
[TBL] [Abstract][Full Text] [Related]
5. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.
De Ramón C; Rojas EA; Cardona-Benavides IJ; Mateos MV; Corchete LA; Gutiérrez NC
Br J Haematol; 2022 Nov; 199(3):344-354. PubMed ID: 35983648
[TBL] [Abstract][Full Text] [Related]
7. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
Chen MH; Qi CX; Saha MN; Chang H
Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
[TBL] [Abstract][Full Text] [Related]
8. p53 haploinsufficiency and functional abnormalities in multiple myeloma.
Teoh PJ; Chung TH; Sebastian S; Choo SN; Yan J; Ng SB; Fonseca R; Chng WJ
Leukemia; 2014 Oct; 28(10):2066-74. PubMed ID: 24625551
[TBL] [Abstract][Full Text] [Related]
9. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
Walker BA; Mavrommatis K; Wardell CP; Ashby TC; Bauer M; Davies F; Rosenthal A; Wang H; Qu P; Hoering A; Samur M; Towfic F; Ortiz M; Flynt E; Yu Z; Yang Z; Rozelle D; Obenauer J; Trotter M; Auclair D; Keats J; Bolli N; Fulciniti M; Szalat R; Moreau P; Durie B; Stewart AK; Goldschmidt H; Raab MS; Einsele H; Sonneveld P; San Miguel J; Lonial S; Jackson GH; Anderson KC; Avet-Loiseau H; Munshi N; Thakurta A; Morgan G
Leukemia; 2019 Jan; 33(1):159-170. PubMed ID: 29967379
[TBL] [Abstract][Full Text] [Related]
10. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.
Lodé L; Eveillard M; Trichet V; Soussi T; Wuillème S; Richebourg S; Magrangeas F; Ifrah N; Campion L; Traullé C; Guilhot F; Caillot D; Marit G; Mathiot C; Facon T; Attal M; Harousseau JL; Moreau P; Minvielle S; Avet-Loiseau H
Haematologica; 2010 Nov; 95(11):1973-6. PubMed ID: 20634494
[TBL] [Abstract][Full Text] [Related]
11. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of
Ye F; Wang T; Liu A; Li Y; Li N; Wang H; Chen W
Turk J Haematol; 2021 Dec; 38(4):246-253. PubMed ID: 33938208
[TBL] [Abstract][Full Text] [Related]
13. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
Boyd KD; Ross FM; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gonzalez D; Walker BA; Hockley SL; Wardell CP; Gregory WM; Child JA; Jackson GH; Davies FE; Morgan GJ;
Genes Chromosomes Cancer; 2011 Oct; 50(10):765-74. PubMed ID: 21961181
[TBL] [Abstract][Full Text] [Related]
14. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma.
Chang H; Yeung J; Qi C; Xu W
Br J Haematol; 2007 Aug; 138(3):324-9. PubMed ID: 17555471
[TBL] [Abstract][Full Text] [Related]
15. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
Corre J; Perrot A; Caillot D; Belhadj K; Hulin C; Leleu X; Mohty M; Facon T; Buisson L; Do Souto L; Lannes R; Dufrechou S; Prade N; Orsini-Piocelle F; Voillat L; Jaccard A; Karlin L; Macro M; Brechignac S; Dib M; Sanhes L; Fontan J; Clement-Filliatre L; Marolleau JP; Minvielle S; Moreau P; Avet-Loiseau H
Blood; 2021 Mar; 137(9):1192-1195. PubMed ID: 33080624
[TBL] [Abstract][Full Text] [Related]
16. Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma.
Liu E; Sudha P; Becker N; Jaouadi O; Suvannasankha A; Lee K; Abonour R; Abu Zaid M; Walker BA
Blood Cancer J; 2023 Sep; 13(1):144. PubMed ID: 37696786
[TBL] [Abstract][Full Text] [Related]
17. Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study.
Goldsmith SR; Fiala MA; Dukeman J; Ghobadi A; Stockerl-Goldstein K; Schroeder MA; Tomasson M; Wildes TM; Vij R
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):285-289. PubMed ID: 30792096
[TBL] [Abstract][Full Text] [Related]
18. Prognosis, Biology, and Targeting of
Flynt E; Bisht K; Sridharan V; Ortiz M; Towfic F; Thakurta A
Cells; 2020 Jan; 9(2):. PubMed ID: 31991614
[TBL] [Abstract][Full Text] [Related]
19. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A.
Elnenaei MO; Gruszka-Westwood AM; A'Hernt R; Matutes E; Sirohi B; Powles R; Catovsky D
Haematologica; 2003 May; 88(5):529-37. PubMed ID: 12745272
[TBL] [Abstract][Full Text] [Related]
20. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
Gao W; Jian Y; Du J; Li X; Zhou H; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
